A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

This study aims to determine the safety and best response of treatment with CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 \[LGR5\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells), for participants with Metastatic Colorectal Cancer. Participants may undergo a pre-screening biopsy procedure to determine expression of LGR5. Participants will undergo screening procedures, including leukapheresis (collection of T cells) and lymphodepletion (chemotherapy), up to 47 days prior to CNA3103 dosing. Participants will receive a single Intravenous dose of CNA3103.

Trial Details

NCT ID
NCT05759728
Phase
PHASE1 / PHASE2
Sponsor
Carina Biotech Limited
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • CNA3103: 5 x 10^7 cells
  • CNA3103: 1.5 x 10^8 cells
  • CNA3103: 4.5 x 10^8 cells
  • CNA3103: 1.5 x 10^9 cells
  • CNA3103: 2.5 x 10^7 cells
  • CNA3103: 6.75 × 10^8 cells
Locations (sample)
  • Adelaide, South Australia, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • Signed written Informed Consent.
  • Male and female subjects aged greater than or equal to18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score 0 to 1.
  • Histologically or cytologically confirmed metastatic colorectal cancer previously treated with no more than 2 prior fluoropyrimidine, oxaliplatin, …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →